Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 3Withdrawn 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × EPOCH protocol × Clear all
NCT00001379 2025-06-19

Treatment and Natural History Study of Lymphomatoid Granulomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
94 enrolled 20 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT00053768 2021-05-18

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Universität des Saarlandes

Phase 3 Completed
392 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡